Needs Statement

This symposium will bring together recognized national and international speakers to address recent advances in diagnosis of myelodysplastic syndrome (MDS) and measurable residual disease [MRD] directed acute myelogenous leukemia (AML) therapy. During our symposium, we will emphasize the need for physicians to combine up-to-date knowledge and technology to efficiently identify “actionable targets” for treatment of AML and MDS patients. Additionally, we expect to gain insight into promising scientific data that would inform therapy efficacy based on AML MRD evaluation. The symposium will provide important novel development in MDS and AML pathogenesis leading to unique opportunity for clinical trial design ideas.

Target Audience

Hematologists, primary care physicians, nurses, nurse practitioners, physician assistants, medical trainees and students

Learning Objectives

At the conclusion of the conference, participants should be able to:

• Summarize current principles that explain clonal hematopoiesis and acute myelogenous leukemia (AML).
• Describe the current role of targeted clonal hematopoiesis and AML genome.
• Integrate complex clonal hematopoiesis and AML into genomic and therapeutic algorithms.
• Discuss the role of targeted agents in the treatment of clonal hematopoiesis and AML in genomic and therapeutic algorithms.

Educational Methods

Lecture, Small Group Breakout Session, and Panel Discussion

Activity Evaluation

Evaluation by questionnaire will address program content, presentation, and possible bias.